Rationale: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like lipoprotein and important cardiovascular risk factor whose cognate receptor and intracellular fate remains unknown.
L ipoprotein(a) [Lp(a)] is an independent risk factor for developing cardiovascular disease.
1 Lp(a) comprises a lowdensity lipoprotein (LDL) with its apolipoprotein B (apoB) moiety linked to apolipoprotein(a) [apo(a)].
2 Apo(a) has its evolutionary origin from plasminogen 3 and shows homology to other plasminogen-related growth factors. 4 Lp(a) is assembled after the secretion of apo(a) from the liver with assembly occurring extracellularly or on the hepatocyte surface 5 or possibly intracellularly before secretion. 6, 7 Factors regulating apo(a) synthesis and secretion are reasonably well understood with the secretion rate of apo(a) being a major determinant of plasma Lp(a) levels. 8 Whereas the anabolic fate of Lp(a) is well established, the catabolic fate of Lp(a) remains uncertain.
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Lp(a) uptake from plasma is primarily via the liver and kidney with liver clearance presumed to predominate. 9 The receptor(s) and mechanism responsible for Lp(a) clearance have yet to be unambiguously identified. Recent studies have identified a role for the scavenger receptor B1 in the uptake of lipids from Lp(a) 10, 11 ; however, the receptor involved in whole Lp(a) particle remains elusive. Multiple receptors have been implicated, but evidence for each is conflicting. This is particularly the case with respect to the LDL receptor (LDLR). Early studies showed that Lp(a) bound to the same high affinity sites as LDL in skin fibroblasts, 12 and its clearance was reduced in fibroblasts from familial hypercholesterolemia homozygotes. 13 This was supported by studies showing that familial hypercholesterolemia subjects had higher Lp(a) levels than nonaffected individuals. 13 Interestingly, recent trials with PCSK9 (proprotein convertase subtilisin/kexin type 9)-specific monoclonal antibodies, which block PCSK9-mediated degradation of the LDLR, show significant reductions in Lp(a) levels. 14, 15 A recent article showed that the LDLR is involved in Lp(a) metabolism in liver and fibroblast cells via its regulation by PCSK9, 16 suggesting that the mechanism responsible for the reduction in Lp(a) levels may be indirectly through an enhanced hepatic LDL uptake. Contrary to these studies implicating a role for LDLR in Lp(a) uptake, many studies have indicated that the LDLR is not involved. Kinetic studies have shown no difference in the catabolism of Lp(a) in familial hypercholesterolemia compared with nonaffected individuals. 17 Furthermore, family studies showed no difference in Lp(a) levels between familial hypercholesterolemia and nonaffected family members with the same apo(a) isoforms. 17, 18 Some cell culture studies have also shown an insignificant role of the LDLR in Lp(a) uptake. 19 Finally, statin treatment, which increases LDLR expression and effectively reduces plasma LDL levels, has no effect on plasma Lp(a) levels in humans. 20, 21 Because evidence for the role of the LDLR in Lp(a) uptake is controversial, the roles of several other potential receptors for Lp(a) catabolism have been investigated. Various studies have implicated a role for the very low-density lipoprotein (VLDL) and megalin/gp330 receptors in Lp(a) uptake 22, 23 ; however, neither receptor is expressed in the liver. Asialoglycoprotein receptor (ASGPR)-dependent Lp(a) uptake was observed in ASGPR −/− mice and COS-7 cells lacking ASGPR 24 ; however, these observations have not been investigated in relevant human cell lines. Previous studies have shown the binding of Lp(a) to plasminogen binding sites on various cell types. 25, 26 Both plasminogen and ε-aminocaproic acid, a lysine analogue that binds to the active site of plasminogen receptors, strongly reduce the binding of recombinant apo(a) to human hepatoma (HepG2) and primary fibroblast cells. 27 However, it is unclear whether these results extend to the intact Lp(a) particle and, if so, which plasminogen receptor(s) are involved. Several plasminogen receptors exist, including α-enolase, H2B, p11/annexinA2, plasminogen receptor (KT; PlgRKT), and α m β 2 integrin. 28 Although multiple receptors could be involved in Lp(a) uptake, a comparison of relevant receptors in the same cellular system has not been made. Furthermore, little is known about the intracellular fate of the Lp(a) particle once internalized. Our study aimed to investigate the internalization and intracellular trafficking route of Lp(a) in human liver and fibroblast cell lines. We show that internalized Lp(a) is trafficked to recycling endosomes via early endosomes and the trans-Golgi network, culminating in the resecretion of apo(a) into the media. Furthermore, we show that the plasminogen receptor, PlgRKT, is largely responsible for Lp(a) uptake.
Methods
Detailed descriptions of the experimental procedures are provided in the Online Data Supplement.
Results

Maximal Lp(a) Uptake Occurs at 2 Hours in HepG2 Cells
Immunostaining for apo(a) using the MAb-a5, apo(a)-specific monoclonal antibody, 29 revealed a lack of endogenous apo(a) at 0 hour and maximum uptake of Lp(a) at 2 hours of Lp(a) treatment (green signal, Figure 1A ) reducing to a minimal signal by 24 hours. Quantification of Lp(a) uptake from Western blots of apo(a) in the cell lysates ( Figure 1B) showed that Lp(a) uptake increased 2-fold between 1 and 2 hours ( Figure 1C ) then decreased down to 0.25-fold at 24 hours. A Western blot of apo(a) in the cell lysates at 6 hours (run under nonreducing conditions) showed the presence of both free apo(a) and Lp(a) ( Figure 1D ), suggesting that Lp(a) dissociates within the cell after internalization. Western blot analysis of apoB in Lp(a)-treated HepG2 cells from 0 to 24 hours (Online Figure IA and IB) and RT-PCR (reverse transcription polymerase chain reaction) analysis of apoB in Lp(a)-treated HepG2 cells at 6 hours (Online Figure IC) indicated continuous endogenous production of apoB not affected by the introduction of exogenous apoB from Lp(a). We also investigated Lp(a) uptake by tracer labeling using AlexaFluor-488-labeled Lp(a). Treatment of HepG2 cells with 5 µg/mL of AlexaFluor-488-labeled Lp(a) showed maximum fluorescence intensity from the internalized Elevated Lp(a) levels are an independent risk factor for cardiovascular disease. There are no current therapies to specifically lower plasma Lp(a) levels. The catabolism of Lp(a) occurs in the liver, but the receptor involved and intracellular fate of the Lp(a) is unknown. We found that Lp(a) is maximally internalized by liver cells within 2 hours where its LDL and apo(a) components have different catabolic fates. Although the LDL component is degraded in the lysosome, apo(a) follows a recycling fate which culminates in apo(a) resecretion. Using gain-and loss-of-function approaches, we show that the receptor mediating the majority of Lp(a) uptake in liver cells is the plasminogen receptor, PlgRKT. These findings provide important new information about Lp(a) catabolism and have implications for the development of therapies to modulate Lp(a) levels.
Lp(a) at 2 hours (100%) with a rapid decrease to 43% by 6 hours and 24% by 24 hours (Online Figure IIA and IIB) . These results are in concordance with the time course of Lp(a) uptake as determined by Western blot and immunostaining.
To track the fate of the lipid and protein components of Lp(a) once internalized, the lipid component of Lp(a) was labeled using DiI stain (1,1'-dilinoleyl-3,3,3',3'-tetramethylindocarbocyanine, 4-chlorobenzenesulfonate), and the apo(a) component was detected as before using an antiapo(a) antibody. Interestingly, the lipid and apo(a) component of Lp(a) were strongly colocalized at 1 and 2 hours (yellow signal, Figure 1E ) but little colocalization was seen after 6 hours of Lp(a) treatment ( Figure 1E ), suggesting the separation of the lipid and apo(a) component of Lp(a) by 6 hours post-Lp(a) internalization.
LDL of Lp(a) Is Degraded via Lysosomes
Because we had observed the separation of the lipid and apo(a) component of Lp(a) (Figure 1E ), we hypothesized that LDL would follow the well-established pathway of LDL degradation via lysosomes. 30 Therefore, we investigated the fate of the LDL part of Lp(a) using Bodipy cholesterol labeling. Treatment of Bodipylabeled Lp(a) onto HepG2 cells for 6 hours at 37°C revealed that the Bodipy-labeled Lp(a) (green signal, Figure 2A ) was strongly colocalized (yellow signal, Figure 2A ) with lysosomes (red signal, Figure 2A ) similar to Bodipy-labeled LDL ( Figure 2A) .
As HepG2 cells synthesize their own apoB making it difficult to visualize the apoB component of Lp(a), we used haploid human fibroblast-like HAP1 cells (which do not express apoB) to determine whether the apoB component also tracked to the lysosomes. ApoB-specific immunostaining of Lp(a) using the 1D1, apoB-specific antibody, 31 revealed that the apoB component of Lp(a) (green signal, Figure 2B ) was strongly colocalized (yellow signal, Figure 2B ) with lysosomes (red signal, Figure 2B ) at 6 hours. Interestingly, the apo(a) component of Lp(a) (green signal, Figure 2C ) showed little colocalization with lysosomes (red signal, Figure 2C ), suggesting that the apo(a) component had a different fate to that of the LDL.
Apo(a) Is not Degraded via Lysosomes or Proteasomes
To further investigate the fate of apo(a), we performed time course studies with organelle-specific immunostaining. As observed with HAP1 cells, there seemed to little colocalization between apo(a) (green signal) and lysosomes (red signal) at any time point ( Figure 2D ). Furthermore, inhibition of lysosomal proteases by NH 4 Cl treatment (which deacidifies the lysosomes) or pharmacologically (using the E64d lysosomal inhibitor) produced no increase in apo(a) levels in cell lysates after 5 µg/mL Lp(a) incubation (Online Figure IIIA and IIIC). In contrast, cells treated with 20 µg/mL LDL showed a distinct increase in intracellular apoB levels after both treatments (Online Figure IIIB and IIID) .
We next investigated whether apo(a) was degraded via the proteasome. Treatment of HepG2 cells with ClastoLactacystin β-lactone, a widely used inhibitor of the 20S proteasome complex, 32 had no effect on either apo(a) or apoB protein levels after Lp(a) or LDL incubation (Online Figure  IIIE and IIIF), confirming that neither apo(a) nor LDL is degraded via the proteasome.
Apo(a) Traffics Through Early Endosomes to the Trans-Golgi Network
As apo(a) was not degraded via lysosomes or proteasomes, we further investigated the intracellular fate of apo(a) using organelle-specific markers. Localization of apo(a) (green) with Rab5-positive early endosomes (red) was observed at 1 and 2 hours of Lp(a) treatment (yellow signal, Figure 3A ). Colocalization of apo(a) and Rab5 diminished with time ≤24 hours ( Figure 3A) , indicative of apo(a) being trafficked elsewhere. Using wheat germ agglutinin to visualize glycosylated proteins present in the trans-Golgi network (red), colocalization of apo(a) (green) was observed at 1 hour (yellow signal, Figure 3B ) and persisted to 24 hours. Little colocalization was observed between apo(a) and the cis/medial Golgi resident protein, giantin (Online Figure IVA) , indicating that apo(a) is mainly present in the trans-Golgi network. Trafficking of apo(a) through the trans-Golgi network was further confirmed when cells were treated with Brefeldin A. Brefeldin A promotes the formation of tubules between the trans-Golgi network and early endosomes 33 and caused the colocalized apo(a) and wheat germ agglutinin (merged, yellow signal; Online Figure IVB ) to extend away from the usual perinuclear location of the trans-Golgi network, indicative of tubule formation. These results suggest that apo(a) is trafficking to the trans-Golgi network via early endosomes, thus avoiding lysosomal and proteasomal degradation.
Apo(a) Is Found Within Recycling Endosomes
We speculated that apo(a) might be found in a recycling endosomal compartment and investigated this after transfecting HepG2 cells with the recycling endosome marker plasmid, dsRed Rab11 wild type (WT). Apo(a) (green) colocalized with dsRed Rab11 WT (red) in the perinuclear region (merged, yellow signal, Figure 4A ) at 6 hours. To confirm that apo(a) was following an intracellular recycling pathway, we investigated the colocalization of apo(a) with exogenously added transferrin to label endogenous intracellular recycling pathways. 34 Coincubation of HepG2 cells with AlexaFluor-594-conjugated transferrin and Lp(a) revealed a strong colocalization between apo(a) (green) and transferrin (red; merged, yellow signal; Figure 4B ). Together, the colocalization of apo(a) with transferrin and Rab11-positive recycling endosomes places the apo(a) component of internalized Lp(a) in the recycling endosomal compartment within liver cells.
Apo(a) Is Resecreted Into the Media
The presence of apo(a) in a recycling compartment begged the question: was apo(a) being resecreted into the media?
To investigate this, HepG2 cells were incubated with Lp(a) for 6 hours, then Lp(a)-containing media removed, and cells extensively washed and placed in fresh media. Western blot analysis showed apo(a) to be present in the fresh media from 1 hour after Lp(a) removal ( Figure 4C ) with levels increasing 2.1-fold by 24 hours compared with 2 hours ( Figure 4D ). To exclude the possibility that the release of surface-bound Lp(a) was the source of apo(a) in the media, HepG2 cells were trypsinized after 6 hours of Lp(a) treatment and reseeded in fresh media for 24 hours to detect the resecreted apo(a) in media. Western blot analysis showed the presence of apo(a) in media from 1 hour post-Lp(a) removal in both washed and trypsinized cells ( Figure 4C ). Because our HepG2 cells are null for apo(a), our results indicate resecretion of the exogenously sourced apo(a).
Further validation that the resecretion of apo(a) was from internalized Lp(a) and not from surface-bound Lp(a) was gained by immunostaining of Lp(a) on the cell surface. There was no evidence of surface-bound Lp(a) (green signal, Online Figure V ) on the HepG2 cell membrane as stained with wheat germ agglutinin (red signal, Online Figure V) , suggesting that the internalized Lp(a), and not cell surface-bound Lp(a), was the source of resecreted apo(a). To establish whether the resecreted apo(a) was in the form of free apo(a) or Lp(a), the resecreted apo(a) was immunoprecipitated from the media and removed from the beads under nonreducing conditions. Western blot analysis showed the presence of both free apo(a) and Lp(a) in the media ( Figure 4E ). However, free apo(a) was first observed at 2 hours, whereas Lp(a) was not observed until 6 hours. Interestingly, the appearance of Lp(a) coincided with the appearance of apoB in the media at 6 hours ( Figure 4C and  4E) . On the basis of this observation, we speculate that free apo(a) may be reassembled into Lp(a) after the endogenous secretion of apoB. Both apo(a) and Lp(a) levels seemed to remain constant in the media from 6 until 24 hours ( Figure 4E ). With respect to how much of the initial apo(a) added to cells was being recycled, quantification of the recycled apo(a) in media by an apo(a)-specific ELISA showed that ≈30% was being recycled into the media after 24 hours ( Figure 4F) .
Finally, the presence of resecreted apo(a) in media was detected after the treatment of HepG2 cells with AlexaFluor-488-labeled Lp(a). Fluorescence in media was seen 6 hours post-Lp(a) removal increasing by 24 hours (Online Figure IIC) . This was in conjunction with the appearance of apo(a) in the media at 6 hours which was increased at 24 hours, as observed by Western blotting of an apo(a) immunoprecipitation from the media (Online Figure  IIC, inset) . Overall, these results corroborate the novel recycling fate of apo(a). Areas marked by white rectangle are zoomed. Scale bar=20 μm. At least 100 cells were analyzed across 3 independent experiments, and representative images are shown. C, HepG2 cells were treated with 5 µg/mL Lp(a) for 6 h at 37°C. After 6 h, Lp(a)-containing media was removed, and cells were either washed with PBS, and fresh serum-free media was added, or cells were trypsinized and reseeded in fresh media for 24 h. Media was then harvested at 1, 2, 6, 12 and 24 h and subject to Lp(a) immunoprecipitation (IP). The Lp(a) IP was subject to Western blot analysis under reducing conditions with the MAb-a5 and 1D1 antibodies using the anti-goat IgG antibody used for the IP as a loading control. D, Apo(a) levels in the Lp(a) IP were normalized to the anti-goat IgG and expressed relative to that of the Lp(a) IP from 1 h post-Lp(a) treatment. Results are expressed as mean±SE for 3 independent experiments performed in triplicate. **P<0.01, ***P<0.001 compared with 1 h post-Lp(a) treatment. E, The Lp(a) IP described in (C) were subjected to Western blot analysis under nonreducing conditions. Lp(a) and apo(a) controls were included. F, The concentration of apo(a) recycled into the media after 24 h compared with the initial amount of Lp(a) added onto HepG2 cells was measured by an apo(a)-specific ELISA. The proportion of recycled Lp(a) in the media relative to the initial Lp(a) added (5 µg/mL) is shown. Results are expressed as mean±SE for 3 experiments performed in triplicates.
Adult Human Dermal Fibroblasts Cells Also Internalize Lp(a) and Resecrete Apo(a) Into the Media
To validate our results of Lp(a) uptake, recycling and resecretion of apo(a) in a primary human cell line, adult human dermal fibroblasts (HDFa), were treated with 5 µg/mL Lp(a). HDFa cells displayed a similar uptake as HepG2 cells ( Figure 5A) ; however, in contrast, the apo(a) signal (green) did not diminish over time. The localization of apo(a) within the cell and recycling endosomes ( Figure 5B and 5D ) was also seen in HDFa cells. Apo(a) was not present in lysosomes in HDFa cells ( Figure 5C ). Like in HepG2 cells, apo(a) was shown to be resecreted into the media ( Figure 5E ) with ≈30% of the initial Lp(a) being resecreted ( Figure 5F ). Because HDFa cells do not secrete endogenous apoB, the resecreted apo(a) cannot be reassembled into Lp(a) as seems to occur in HepG2 cells.
Lp(a) Uptake Is Independent of the LDLR and ASGPR
Last, we wanted to determine the receptor responsible for Lp(a) internalization. We investigated whether the LDLR was responsible for Lp(a) uptake. Preincubation of HepG2 cells with an anti-LDLR antibody followed by Lp(a) treatment of HepG2 cells showed no change in Lp(a) uptake ( Figure 6A ). LDL uptake, however, was markedly reduced ( Figure 6A ) by the LDLR antibody. Confocal microscopy performed on Lp(a)-treated HepG2 cells showed little colocalization between internalized apo(a) (green signal) and the LDLR (red) ( Figure 6D ). We next investigated whether the ASGPR was involved in Lp(a) uptake. Coincubation of GalNAc, a natural ligand for the ASGPR, and Lp(a) in HepG2 cells did not alter Lp(a) uptake ( Figure 6B ). Blocking the ASGPR by preincubating HepG2 cells with an anti-ASGPR1 antibody did not alter Lp(a) uptake ( Figure 6B ). There was no colocalization observed between internalized apo(a) (green signal) and ASGPR (red) on confocal microscopy of HepG2 cells ( Figure 6E ). Together, these results suggest that neither the AGSPR nor LDLR is the receptor responsible for Lp(a) internalization.
Plasminogen Receptor, PlgRKT, Is Responsible for the Majority of Lp(a) Uptake
Because of the high homology of apo(a) with plasminogen, 3 we hypothesized that Lp(a) uptake might be mediated via plasminogen receptors. PlgRKT is a recently identified plasminogen receptor that is hypothesized to be the predominant plasminogen receptor in humans. 35 Coincubation of Lp(a) with ε-aminocaproic acid for 6 hours severely reduced apo(a) uptake (Figure 6C ), as did preincubation of the cells with an anti-PlgRKT antibody before Lp(a) treatment ( Figure 6C ).
Confocal microscopy of Lp(a)-treated HepG2 cells showed colocalization between the internalized apo(a) (green signal) and PlgRKT (red signal; merged, yellow signal; Figure 6F ).
To investigate the role of the PlgRKT in mediating Lp(a) uptake, PlgRKT −/− HAP1 cells were obtained. PlgRKT −/− HAP1 cells were shown to have no detectable PlgRKT as detected by Western blot analysis, whereas the receptor was detected in WT HAP1 cells (Online Figure VIA) . Treatment of both cell lines with 5 µg/mL Lp(a) for 6 hours showed Lp(a) uptake to be markedly reduced in PlgRKT −/− cells ( Figure 7A ) compared with WT HAP1 cells (0.35-fold reduction). The lack of LDLR involvement in Lp(a) uptake was further confirmed when blocking of the LDLR with an anti-LDLR antibody in HAP1 PlgRKT −/− cells had no cumulative effects on Lp(a) uptake (Online Figure VIIA) . Control experiments showed that neither LDL nor plasminogen uptake was affected in HAP1 PlgRKT −/− cells (Online Figure VIIIA and VIIIB). The lack of an effect of the PlgRKT on plasminogen uptake was confirmed by a plasminogen competition assay which showed that plasminogen did not compete with Lp(a) in HepG2 cells Figure 6 . Lipoprotein(a) [Lp(a)] uptake is independent of the low-density lipoprotein receptor (LDLR) and asialoglycoprotein receptor (ASGPR) and is mediated by the PlgRKT plasminogen receptor. A, Human hepatoma (HepG2) cells were preincubated with 10 μg/mL anti-LDLR followed by incubation with 5 μg/mL Lp(a) or 20 μg/mL LDL at 37°C for 6 h. B, HepG2 cells were either treated with 5 μg/mL Lp(a) and 20 µmol/L GalNAc or preincubated with 5 μg/mL anti-ASGPR1 followed by 5 μg/mL Lp(a) at 37°C for 6 h. C, HepG2 cells were either treated with 5 µg/mL Lp(a) and 5 µmol/L ɛ-aminocaproic acid (ɛ-ACA) or preincubated with 10 µg/mL anti-PlgRKT antibody followed by 5 μg/mL Lp(a) at 37°C for 6 h. Cell lysates were subjected to Western blotting with MAb-a5 and 1D1 antibodies using actin as a loading control. Each experiment was done in triplicates of at least 2 independent experiments, and representative blots are shown. Confocal microscopy of Lp(a)-treated HepG2 cells stained with MAb-a5, detected by an anti-mouse AlexaFluor-488 antibody, (D) LDLR staining with an anti-LDLR antibody detected by an anti-rabbit AlexaFluor-594 antibody, (E) ASGPR staining with an anti-ASGPR1 antibody detected by an anti-rabbit AlexaFluor-647 antibody, and (F) PlgRKT staining with an anti-PlgRKT antibody detected by an anti-rabbit AlexaFluor-594 antibody. Merged images with DAPI are shown. Areas marked by white rectangle are zoomed. Scale bar=20 μm. At least 100 cells were analyzed per condition across 3 independent experiments, and representative images are shown.
(Online Figure VIIB) . Overall, these results demonstrate that the PlgRKT receptor specifically mediates Lp(a) uptake independent of the LDLR, and its role in plasminogen uptake in these cells is minimal.
An siRNA-mediated knockdown of the human PlgRKT gene was also performed in HepG2 cells to strengthen the role of the PlgRKT-mediated Lp(a) uptake in HepG2 cells. Transfection of HepG2 cells with 30 nmol/L PlgRKT-specific siRNA showed reduced PlgRKT levels (Online Figure VIC) . The PlgRKT-specific siRNA transfection followed by treatment with 5 µg/mL Lp(a) for 6 hours showed a significant reduction in Lp(a) internalization to 0.33-fold relative to untransfected HepG2 cells ( Figure 7C ).
To further corroborate the role of the PlgRKT in mediating Lp(a) uptake, the human PlgRKT gene was overexpressed in both WT HAP1 and HepG2 cells. An increase in the PlgRKT protein level was apparent in HAP1 and HepG2 cells (Online Figure VIB and VID, respectively) , which was associated with a 2-fold increase in Lp(a) uptake in HAP1 ( Figure 7B ) and a 1.6-fold increase in HepG2 cells ( Figure 7D ) relative to untransfected cells. Collectively, these results suggest that the plasminogen receptor, PlgRKT, plays a significant role in mediating Lp(a) uptake.
Discussion
The liver has been established as the predominant site for Lp(a) catabolism 8 ; however, the receptor involved in Lp(a) uptake has not been well established, and the intracellular fate of Lp(a) has never been reported. Here, we show the timedependent uptake of Lp(a) in liver cells using immunostaining and tracer-labeling experiments. We also show that the plasminogen receptor, PlgRKT, plays a significant role in Lp(a) uptake and that after Lp(a) internalization, the apo(a) component is trafficked to recycling endosomes which subsequently facilitate resecretion of the protein (Figure 8 ). In contrast, the LDL component is trafficked to the lysosome for degradation. These findings have implications for the metabolism of Lp(a) and function of apo(a) which we subsequently discuss and −/− cells were treated with 5 µg/mL Lp(a) for 6 h at 37°C, and cell lysates were subjected to Western blot with MAb-a5 using actin as a loading control. Apo(a) protein levels were normalized to actin and expressed relative to HAP1 WT cells. Results are expressed as mean±SEM for at least 2 experiments performed in triplicate. ****P<0.0001 compared with HAP1 WT cells. B, HAP1 WT cells were transfected with a plasmid containing the human PlgRKT gene and were subsequently treated with 5 µg/mL Lp(a) for 6 h at 37°C. Cell lysates were subjected to Western blot with MAb-a5 using actin as a loading control. Apo(a) protein levels in cell lysates were normalized to actin and expressed relative to untransfected HAP1 WT cells. Results are expressed as mean±SEM for triplicate blots. **P<0.01 compared with untransfected HAP1 WT cells. C, Human hepatoma (HepG2) cells were transfected with a PlgRKT-specific siRNA and subsequently treated with 5 µg/mL Lp(a) for 6 h at 37°C, and cell lysates were subjected to Western blot with MAb-a5 using actin as a loading control. Apo(a) protein levels in cell lysates were normalized to actin and expressed relative to untransfected HepG2 cells. Results are expressed as mean±SEM for at least 2 experiments performed in triplicates. **P<0.01 compared with untransfected HepG2 cells. D, HepG2 cells were transfected with a plasmid containing the human PlgRKT gene and were subsequently treated with 5 µg/mL Lp(a) for 6 h at 37°C, and cell lysates were subjected to Western blot with MAb-a5 using actin as a loading control. Apo(a) protein levels were normalized to actin and expressed relative to untransfected HepG2 cells. Results are expressed as mean±SEM for triplicate blots. **P<0.01 compared with untransfected HepG2 cells.
provide useful knowledge for the future design of therapies aimed at enhancing Lp(a) catabolism.
Because of the similarity of Lp(a) to LDL, we expected that Lp(a) catabolism might follow the LDLR pathway as established by Brown and Goldstein 30 in which LDL is degraded by lysosomes after LDLR-facilitated internalization. Certainly, evidence for Lp(a) being catabolized by the LDLR has been presented, [12] [13] [14] [15] [16] although for every article that suggested involvement there was one to suggest otherwise. [17] [18] [19] [20] [21] Here, we present evidence that Lp(a) does not interact with the LDLR, including no interference of Lp(a) uptake by an LDLR antibody that blocks LDL uptake and no colocalization between apo(a) and LDLR in liver cells. Our results are in concordance with a recent study showing that Lp(a) uptake in both primary hepatocytes and fibroblasts cells are unaffected by PCSK9-specific monoclonal antibody treatment, indicating no role for the LDLR, 36 but are in contrast with another recent study showing that Lp(a) uptake in hepatocytes and fibroblasts is affected by PCSK9-specific monoclonal antibody treatment implying the involvement of the LDLR. 16 Labeling of the lipid and protein components of Lp(a) showed that the internalized Lp(a) is dissociated into the LDL and apo(a) moieties within 6 hours. The 2 components then follow different fates. Labeling of the lipid and apoB component of Lp(a) showed that the LDL part of Lp(a) is found in lysosomes 6 hours after Lp(a) treatment. The apo(a) component, on the other hand, does not traffic to lysosomes as seen by a lack of colocalization between apo(a) and lysosomes in both liver and fibroblast cells and a lack of apo(a) accumulation after treatment with lysosomal inhibitors. Our experiments tracking the fate of apo(a) via apo(a)-specific immunohistochemistry led us to find that apo(a) was trafficked to the trans-Golgi network via Rab5-positive early endosomes and from there was placed into Rab11-positive recycling endosomes resulting in apo(a) being secreted back into the media (Figure 8 ). The apo(a) observed in the media was initially free but seemed to be reassembled into Lp(a) in association with the appearance of apoB particles secreted from HepG2 cells. This is in keeping with studies showing an extracellular assembly of Lp(a) in cell culture media. 37 Resecretion of free apo(a) was further confirmed after the incubation of primary fibroblasts with Lp(a) showed free apo(a) appearing in the media on a similar time scale and concentration to that seen in HepG2 cells. A tracer experiment with AlexaFluor-488-labeled Lp(a) validated the resecretion of apo(a) into the media. Exactly at what point the apo(a) is released from the intact Lp(a) particle is not known, but free apo(a) appears in the cell lysate by 1 to 2 hours. A previous study using FRET imaging has shown that disulphide bond reduction activity is found in many endosomal compartments but not in lysosomes or the Golgi apparatus. 38 This suggests that apo(a) may be released from LDL in either the early or recycling endosomal compartments. However, the location and mechanism for apo(a) release remain unknown.
To further confirm the recycling of apo(a), we looked whether apo(a) colocalizes with a classic recycled protein, transferrin. 34 Indeed, colocalization of apo(a) and transferrin was apparent. None of the plasminogen family members have previously been reported as being recycled so the finding that apo(a) is recycled is novel and raises many questions most notably why is it recycled? Recycling proteins often have functional roles in carrying extracellular ligands into the cell. In the case of transferrin, the ligand is extracellular iron.
34 Apo(a) is known to bind many ligands, including oxidized phospholipids and fibrin. 39, 40 Recycled apo(a) may be involved in the removal of oxidized phospholipids from cell surfaces with the apo(a)/oxidized phospholipids complex being delivered via the scavenger receptor B1 receptor 9 after reformation of Lp(a). Alternatively, recycled apo(a) could be involved in the clearance of fibrin degradation products from circulation because proteomic studies have revealed that all 3 fibrin chains peptides are present on the apo(a) component of Lp(a). 41 Interestingly, recycling of apolipoproteins is not unprecedented. Previous studies have shown that a significant portion of apolipoprotein E (apoE) escapes degradation by lysosomes 42 and is rerouted via the Golgi for resecretion. The recycled apoE has been proposed to play a role in lipoprotein assembly, cholesterol efflux, and chylomicron clearance. Likewise, recycled apo(a) might have some physiological relevance in Lp(a) metabolism.
The finding that apo(a) is recycled could have implications for Lp(a) kinetic studies because this would suggest that there may be 2 pools of Lp(a) in circulation, one initially assembled from newly secreted apo(a) and another formed later from reassembly of Lp(a) after apo(a) resecretion. Interestingly, previous kinetic studies have identified that apo(a) has a significantly reduced fractional catabolic rate compared with the apoB within Lp(a), suggesting that the apo(a) component has a longer plasma resident time than the apoB. 44, 45 The authors from both studies concluded that this was likely because of the dissociation of apo(a) from Lp(a) and its reassociation with other apoB-containing particles in plasma. We propose that the extended plasma resident time of apo(a) might be in part because of the recycling of apo(a) from the liver effectively creating 2 pools of Lp(a). Nonetheless, some kinetic studies have shown similar fractional catabolic rates for the apo(a) and apoB components of Lp(a) arguing against the presence of 2 pools of Lp(a) in circulation. 7, 46, 47 Clearly, further studies are needed to elucidate whether recycled apo(a) makes a significant contribution to the plasma pool of Lp(a).
Our findings might also bear some light on previous studies reporting the excretion of free apo(a) in urine. 48 Our study showing the resecretion of free apo(a) may suggest that free apo(a) is available for degradation via the kidney if it is not reassembled back into Lp(a). It is possible that the recycled apo(a) is further modified from its original form which may make it a better substrate for metabolism by the kidney. Further studies are required to determine this.
We showed that Lp(a) internalization is regulated by the plasminogen receptor, PlgRKT, after knockout of this receptor in a haploid fibroblast-like HAP1 cell line, and a PlgRKTspecific siRNA knockdown of this receptor in HepG2 cells significantly reduced Lp(a) uptake. Similarly, the overexpression of the PlgRKT significantly enhanced Lp(a) uptake in both cell lines. Because of the high homology of apo(a) with plasminogen, it is perhaps not surprising that apo(a) would interact with plasminogen receptors. Indeed, earlier studies had shown Lp(a) to interact with plasminogen binding sites on the surface of U937 and endothelial cells, 24 and lysine analogues and plasminogen disrupted binding of apo(a) to cell surface receptors. 25 Interestingly, PlgRKT contains an exposed C-terminal lysine residue which is important for its interaction with plasminogen 34 and presumably apo(a). However, because complete knockout of PlgRKT only reduced 65% of apo(a) uptake, it remains possible that other plasminogen receptors such as p11/annexinA2 may be responsible for further Lp(a) uptake. Furthermore, our study used a limited range of apo(a) size isoforms, and it would be of interest to evaluate the effect of different sizes of apo(a) on PlgRKT-mediated uptake and recycling of apo(a) in future studies.
In conclusion, we show 2 novel findings for Lp(a) metabolism namely that Lp(a) internalization is mediated by the plasminogen receptor, PlgRKT, and that after internalization, the apo(a) protein is resecreted to the extracellular space via recycling endosomes (Figure 8 ). The identification of a receptor for Lp(a) catabolism has implications for manipulations of Lp(a) levels. At present, there is only 1 therapy, apo(a) antisense, that can specifically lower Lp(a), and this is targeted at reducing apo(a) synthesis. 49 Drugs targeted at increasing catabolism will add to the repertoire of possible Lp(a)-lowering therapies so that in the future, like LDL, we may have multiple agents with which to intervene and lower Lp(a) and associated cardiovascular disease risk.
